Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series

Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines. Eculizumab appears to be the treatment of choice for aHUS and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical case reports 2022-03, Vol.10 (3), p.e05573-n/a
Main Authors: Vitkauskaitė, Monika, Vinikovas, Artūras, Miglinas, Marius, Rimševičius, Laurynas, Čerkauskaitė, Agnė, Mačionienė, Ernesta, Ašakienė, Eglė
Format: Article
Language:English
Subjects:
Anemia
atypical hemolytic uremic syndrome
Autoimmune diseases
Biopsy
Blood platelets
Blood tests
Case Report
Case Reports
complement
Dehydrogenases
Disease
eculizumab
Females
Hematology
Hemodialysis
Hemoglobin
Hospitals
Kidney transplants
Kinases
Laboratories
Lupus
Monoclonal antibodies
Mutation
nephrology
Oliguria
Patients
Proteins
Steroids
Thrombocytopenia
thrombotic microangiopathy
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines. Eculizumab appears to be the treatment of choice for aHUS and secondary TMA, especially in those who have failed standard therapy. Our case series confirm the benefit of eculizumab in both, aHUS and sTMA, showing hematologic and renal recovery along with cessation of immunological damage in the patient.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.5573